Regatta Bio

Executive Summary

Regatta Bio is a private biotechnology company based in Boston, founded in 2021, focused on developing next-generation engineered regulatory T cell (Treg) therapies. The company aims to create scalable, precise, and durable treatments for chronic Graft-versus-Host Disease (GvHD), solid organ transplant rejection, and autoimmune disorders by overcoming the limitations of traditional immunosuppressive drugs. With a mission to leverage Treg cell engineering, Regatta Bio is positioned in the competitive cell therapy landscape, targeting high-unmet-need indications. While still in early preclinical stages without disclosed funding or pipeline details, the company's approach holds promise for addressing immune-mediated diseases with greater specificity and durability.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement70% success
• Q1 2027Preclinical Proof-of-Concept Data Release60% success
• Q2 2027IND Filing for Lead Candidate40% success